SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Itraconazole 10 mg/ml Oral Solution.

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 1 ml of solution contains 10mg itraconazole.

Excipient(s) with known effect: contains 190 microlitres of sorbitol E420, 0.07mmol (1.56mg) sodium and less than 1mg ethanol per ml of solution.

For the full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM

Oral solution.

Clear yellow solution.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications

Itraconazole Oral Solution is indicated in adults:

- For the treatment of oral and/or oesophageal candidosis in HIV-positive or other immunocompromised patients.

- As prophylaxis of deep fungal infections anticipated to be susceptible to itraconazole, when standard therapy is considered inappropriate, in patients with haematological malignancy or undergoing bone marrow transplant, and who are expected to become neutropenic (ie < 500 cells/µl). At present there are insufficient clinical efficacy data in the prevention of aspergillosis.

Consideration should be given to national and/or local guidance regarding the appropriate use of antifungal agents.

4.2 Posology and method of administration

Posology

For optimal absorption, Itraconazole Oral Solution should be taken without food (patients are advised to refrain from eating for at least 1 hour after intake).

Treatment of oral and/or oesophageal candidosis: 200 mg (20ml) per day in two intakes, or alternatively in one intake, for 1 week. If there is no response after 1 week, treatment should be continued for another week.

Treatment of fluconazole resistant oral and/or oesophageal candidosis: 100 to 200 mg (10-20ml) twice daily for 2 weeks. If there is no response after 2 weeks, treatment should be continued for another 2 weeks. The 400mg daily dose should not be used for longer than 14 days if there are no signs of improvement.

Prophylaxis of fungal infections: 5 mg/kg per day administered in two intakes. In clinical trials, prophylaxis treatment was started immediately prior to the cytostatic treatment and generally one week before transplant procedure. Almost all proven deep fungal infections occurred in patients reaching neutrophil counts below 100 cells/µl. Treatment was continued until recovery of neutrophils (ie > 1000 cells/µl).

Pharmacokinetic parameters from clinical studies in neutropenic patients demonstrate considerable intersubject variation. Blood level monitoring should be considered particularly in the presence of gastrointestinal damage, diarrhoea and during prolonged courses of Itraconazole Oral Solution.

Use in patients with gastro-intestinal motility impairment: When treating patients with severe fungal infections or when administering it as fungal prophylaxis to those with abnormal gastro-intestinal motility, patients should be carefully monitored and where appropriate drug therapeutic monitoring should be considered, where available.

Paediatric population

The safety and efficacy of Itraconazole Oral Solution in children has not been established. Currently available data are described in section 4.4 and 5.2 but no recommendation on a posology can be made.

The use of Itraconazole Oral Solution in paediatric patients is not recommended unless it is determined that the potential benefit outweighs the potential risks (see section 4.4).

Prophylaxis of fungal infections: there are no efficacy data available in neutropenic children. Limited safety experience is available with a dose of 5 mg/kg per day administered in two intakes (see section 4.8)

Use in elderly

Since clinical data on the use of Itraconazole Oral Solution in elderly patients is limited, it is advised to use Itraconazole Oral Solution in these patients only if the potential benefit outweighs the potential risks. In general, it is

recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (See section 4.4).

Use in patients with hepatic impairment

Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when this drug is administered in this patient population. (See section 5.2)

Use in patients with renal impairment

Limited data are available on the use of oral itraconazole in patients with renal impairment. The exposure of itraconazole may be lower in some patients with renal insufficiency and a wide inter-subject variation was observed in these subjects receiving the capsule formulation (see section 5.2). Caution should be exercised when this drug is administered in this patient population and adjusting the dose or switching to an alternative antifungal medication may be considered based on an evaluation of clinical effectiveness.

Method of administration

For the treatment of oral and/or oesophageal candidosis, the liquid should be swished around the oral cavity (approx. 20 seconds) and swallowed. There should be no rinsing after swallowing.

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Co-administration of a number of CYP3A4 substrates is contraindicated with Itraconazole Oral Solution (see section 4.4 and 4.5).

Itraconazole Oral Solution should not be administered to patients with evidence of ventricular dysfunction such as congestive heart failure (CHF) or a history of CHF except for the treatment of life-threatening or other serious infections (see section 4.4).

Itraconazole Oral Solution should not be used during pregnancy for non-life-threatening indications (see section 4.6).

Co-administration of a number of CYP3A4 substrates is contraindicated with Itraconazole Oral Solution (see sections4.4 and 4.5). These include:

Analgesics; Anaesthetics		
Ergot alkaloids (e.g. dihydroergotamine,ergometrine, ergotamine,methylergometrine)		
Anti-bacterials for Systemic Use; Anti-mycobacterials; Antimycotics for Systemic Use		
Isavuconazole		
Anthelmintics; Antiprotozoals		
Halofantrine		
Antihistamines for Systemic Use		
Astemizole	Mizolastine	Terfenadine
Antineoplastic Agents		
Irinotecan		
Antithrombotic Agents		
Dabigatran	Ticagrelor	
Antivirals for Systemic Use		
Ombitasvir/Paritaprevir/Ritonavir(with or without Dasabuvir)		
Cardiovascular System (Agents Acting on the Renin-Angiotensin System; Antihypertensives; Beta Blocking Agents; Calcium Channel Blockers; Cardiac Therapy; Diuretics)		
Aliskiren	Dronedarone	Nisoldipine
Bepridil	Eplerenone	Quinidine
Disopyramide	Ivabradine	Ranolazine
Dofetilide	Lercanidipine	Sildenafil (pulmonary hypertension)

Gastrointestinal Drugs, including Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents; Antiemetics and Antinauseants; Drugs for Constipation; Drugs for Functional Gastrointestinal Disorders		
Cisapride	Domperidone	Naloxegol
Lipid Modifying Agents		
Lovastatin	Lomitapide	Simvastatin
Psychoanaleptics; Psycholeptics (eg, antipsychotics, anxiolytics, and hypnotics)		
Lurasidone	Pimozide	Sertindole
Midazolam (oral)	Quetiapine	Triazolam
Urologicals		
Avanafil	Darifenacin	Solifenacin (in patients with severe renal impairment or moderate to severe hepatic impairment)
Dapoxetine	Fesoterodine (in patients with moderate or severe renal or hepatic impairment).	Vardenafil (in patients older than75 years).
Miscellaneous Drugs and Other Substances		
Colchicine (in patients with renal or hepatic impairment)	Eliglustat (in patients that are CYP2D6 poor metabolisers (PM), CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers(EMs) that are taking a strong or moderateCYP2D6 inhibitor).	

4.4 Special warnings and precautions for use

Use in patients with gastro-intestinal motility impairment

When treating patients with severe fungal infections or when administering it as fungal prophylaxis to those with abnormal gastro-intestinal motility,

patients should be carefully monitored and where appropriate drug therapeutic monitoring should be considered, where available.

Cross-hypersensitivity

There is no information regarding cross hypersensitivity between itraconazole and other azole antifungal agents. Caution should be used in prescribing Itraconazole Oral Solution to patients with hypersensitivity to other azoles.

Cardiac effects

In a healthy volunteer study with itraconazole IV, a transient asymptomatic decrease of the left ventricular ejection fraction was observed.

Itraconazole has been shown to have a negative inotropic effect and itraconazole has been associated with reports of congestive heart failure. Heart failure was more frequently reported among spontaneous reports of 400mg total daily dose than among those of lower total daily doses, suggesting that the risk of heart failure might increase with the total daily dose of itraconazole.

Itraconazole Oral Solution should not be used in patients with congestive heart failure or with a history of congestive heart failure unless the benefit clearly outweighs the risk. This individual benefit/risk assessment should take into consideration factors such as the severity of the indication, the dose and duration of the treatment, and individual risk factors for congestive heart failure. Such patients should be informed of the signs and symptoms of congestive heart failure, should be treated with caution, and should be monitored for signs and symptoms of congestive heart failure during treatment; if such signs or symptoms do occur during treatment, Itraconazole Oral Solution should be discontinued.

Caution should be exercised when co-administering itraconazole and calcium channel blockers (see section 4.5).

Hepatic effects

Very rare cases of serious hepatotoxicity, including some cases of fatal acute liver failure, have occurred with the use of itraconazole. Some of these cases involved patients with no pre-existing liver disease. Some of these cases have been observed within the first month of treatment, including some within the first week. Liver function monitoring should be considered in patients receiving itraconazole treatment. Patients should be instructed to promptly report to their physician signs and symptoms suggestive of hepatitis such as anorexia, nausea, vomiting, fatigue, abdominal pain or dark urine. In these patients treatment should be stopped immediately and liver function testing should be conducted. Most cases of serious hepatotoxicity involved patients who had pre-existing liver disease, were treated for systemic indications, had significant other medical conditions and/or were taking other hepatotoxic drugs.

Paediatric population

Clinical data on the use of Itraconazole Oral Solution in paediatric patients are limited. The use of Itraconazole Oral Solution in paediatric patients is not recommended unless it is determined that the potential benefit outweighs the potential risks.

Use in elderly

Since clinical data on the use of Itraconazole Oral Solution in elderly patients is limited, it is advised to use Itraconazole Oral Solution in these patients only if the potential benefit outweighs the potential risks. In general, it is recommended that the dose selection for an elderly patient should be taken into consideration, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see section 4.4).

Hepatic impairment

Limited data are available on the use of oral itraconazole in patients with hepatic impairment. Caution should be exercised when the drug is administered in this patient population. It is recommended that patients with impaired hepatic function be carefully monitored when taking itraconazole. It is recommended that the prolonged elimination half-life of itraconazole observed in the single oral dose clinical trial with itraconazole capsules in cirrhotic patients be considered when deciding to initiate therapy with other medications metabolized by CYP3A4 (.
In patients with elevated or abnormal liver enzymes or active liver disease, or who have experienced liver toxicity with other drugs, treatment with Itraconazole should not be started unless there is a serious or life-threatening situation where the expected benefit exceeds the risk of hepatic injury. In patients with pre-existing hepatic function pre-existing hepatic function abnormalities or those who have experienced liver toxicity, liver function should be carefully monitored when taking itraconazole with other medications (see section 5.2).

Renal impairment

Limited data are available on the use of oral itraconazole in patients with renal impairment. The exposure of Itraconazole may be lower in some patients with renal insufficiency and a wide inter-subject variation was observed in these subjects receiving the capsule formulation (see section 5.2). Caution should be exercised when this drug is administered in this patient population and adjusting the dose or switching to an alternative antifungal medication may be considered based on an evaluation of clinical effectiveness.

Prophylaxis in neutropenic patients

In clinical trials diarrhoea was the most frequent adverse event. This disturbance of the gastrointestinal tract may result in impaired absorption and may alter the microbiological flora potentially favouring fungal colonisation.

Consideration should be given to discontinuing Itraconazole Oral Solution in these circumstances.

Treatment of severely neutropenic patients

Itraconazole Oral Solution as treatment for oral and/or esophageal candidosis was not investigated in severely neutropenic patients. Due to the pharmacokinetic properties (see 5.2 Pharmacokinetic properties), Itraconazole Oral Solution is not recommended for initiation of treatment in patients at immediate risk of systemic candidosis.

Hearing Loss

Transient or permanent hearing loss has been reported in patients receiving treatment with itraconazole. Several of these reports included concurrent administration of quinidine which is contraindicated (see sections 4.3 and 4.5). The hearing loss usually resolves when treatment is stopped, but can persist in some patients.

Cystic fibrosis

In cystic fibrosis patients, variability in plasma levels of itraconazole leading to subtherapeutic concentrations has been observed. The risk for subtherapeutic concentrations may be higher in < 16 year olds. If a patient does not respond to Itraconazole Oral Solution, consideration should be given to switching to Itraconazole IV or to alternative therapy.

Neuropathy

If neuropathy occurs that may be attributable to Itraconazole Oral Solution, the treatment should be discontinued.

Cross-resistance

In systemic candidosis, if fluconazole-resistant strains of *Candida* species are suspected, it cannot be assumed that these are sensitive to itraconazole, hence their sensitivity should be tested before the start of itraconazole therapy.

Interaction potential

Itraconazole Oral Solution has a potential for clinically important drug interactions (see section 4.5).

Coadministration of specific drugs with itraconazole may result in changes in efficacy or safety of itraconazole and/or the coadministered drug. For example, the use of itraconazole with CYP3A4 inducing agents may lead to sub-therapeutic plasma concentrations of itraconazole and thus treatment failure. In addition, the use of itraconazole with some substrates of CYP3A4 can lead to increases in plasma concentrations of these drugs and to serious and/or

potentially life threatening adverse events, such as QT prolongation and ventricular tachyarrhythmias including occurrences of torsade de pointes, a potentially fatal arrhythmia. The prescriber should refer to the co-administered medicinal product information for further information regarding serious or life threatening adverse events that could occur in cases of increased plasma concentrations for that medication. For recommendations concerning the coadministration of medicinal products which are contraindicated, not recommended or recommended for use with caution in combination with itraconazole please refer to section 4.3 and 4.5.

.

Interchangeability

It is not recommended that Itraconazole Capsules and Itraconazole Oral Solution be used interchangeably. This is because drug exposure is greater with the Oral Solution than with the Capsules when the same dose of drug is given.

Excipients of Itraconazole Oral Solution

Itraconazole Oral Solution contains sorbitol. Patients with rare hereditary problems of fructose intolerance should not be given this medicine.

This medicinal product contains 0.07mmol (1.56mg) sodium per ml of solution. To be taken into consideration by patients on a controlled sodium diet.

The flavouring used in this medicinal product contains small amounts of ethanol (alcohol), less than 1mg per 1ml of solution.

4.5 Interaction with other medicinal products and other forms of interaction

Itraconazole is mainly metabolized through CYP3A4. Other substances that either share this metabolic pathway or modify CYP3A4 activity may influence the pharmacokinetics of itraconazole. Itraconazole is a strong CYP3A4 inhibitor and, a P-glycoprotein inhibitor and Breast Cancer Resistance Protein (BCRP) inhibitor.
Itraconazole may modify the pharmacokinetics of other substances that share this metabolic or these protein transporter pathways.

Examples of drugs that may impact on the plasma concentration of itraconazole are presented by drug class in Table 1below. Examples of drugs that may have their plasma concentrations impacted by itraconazole are presented in Table 2below. Due to the number of interactions, the potential changes in safety or efficacy of the interacting drugs are notincluded. Please refer to the prescribing information of the interacting drug for more information.

The interacting drugs are categorized as contraindicated, not recommended or to be used with caution with itraconazole taking into account the extent of the concentration increase and the safety profile of the interacting drug (see also sections 4.3 and 4.4 for further information). The interaction potential of the listed drugs was evaluated based on human pharmacokinetic studies with itraconazole, and/or human pharmacokinetic studies with other strong CYP3A4 inhibitors (e.g. ketoconazole) and/or in vitro data:

- 'Contraindicated': Under no circumstances is the drug to be co-administered with itraconazole, and up to two weeks after discontinuation of treatment with itraconazole.
- 'Not recommended': The use of the drug be avoided during and up to two weeks after discontinuation of treatment with itraconazole, unless the benefits outweigh the potentially increased risks of side effects. If co-administration cannot be avoided, clinical monitoring for signs or symptoms of increased or prolonged effects or side effects of the interacting drug is recommended, and its dosage be reduced or interrupted as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured.
- 'Use with caution': Careful monitoring is recommended when the drug is co-administered with itraconazole. Upon coadministration, it is recommended that patients be monitored closely for signs or symptoms of increased or prolonged effects or side effects of the interacting drug, and its dosage be reduced as deemed necessary. When appropriate, it is recommended that plasma concentrations be measured.

The interactions listed in these tables have been characterised in studies that were performed with recommended dose of itraconazole. However, the extent of interaction may be dependent on the dose of itraconazole administered. A stronger interaction may occur at a higher dose or with a shorter dosing interval. Extrapolation of the findings with other dosing scenarios or different drugs should be done with caution.
Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within7 to 14 days, depending on the dose and duration of treatment. In patients with hepatic cirrhosis or in subjects receivingCYP3A4 inhibitors, the decline in plasma concentrations may be even more gradual. This is particularly important when initiating therapy with drugs whose metabolism is affected by itraconazole. (see section 5.2)

Table 1: Examples of drugs that may impact the plasma concentration of itraconazole, presented by drug class

Medicinal products Per Oral [PO] Single Dose unless otherwise stated) within class	**Expected/Potential effect on itraconazole levels (↑ = increase; ↔ = no change; ↓ = decrease)**	**Clinical comment (see above for additional info and also sections 4.3 and 4.4)**

Anti-bacterials for Systemic Use; Anti-mycobacterials		
Isoniazid	Although not studied directly, isoniazid is likely to decrease the concentrations of itraconazole.	Not recommended
Rifampicin PO 600 mg OD	Itraconazole AUC ↓	Not recommended
Rifabutin PO 300 mg OD	Itraconazole Cmax ↓ 71%, AUC ↓ 74%	Not recommended
Ciprofloxacin PO 500 mg BID	Itraconazole Cmax ↑ 53%, AUC ↑ 82%	Use with caution
Erythromycin 1 g	Itraconazole Cmax ↑ 44%, AUC ↑ 36%	Use with caution
Clarithromycin PO 500 mg BID	Itraconazole Cmax ↑ 90%, AUC ↑ 92%	Use with caution
Antiepileptics		
Carbamazepine, Phenobarbital	Although not studied directly, these drugs are likely to decrease concentrations of itraconazole.	Not recommended
Phenytoin PO 300 mg OD	Itraconazole Cmax ↓ 83%, AUC ↓ 93% Hydroxyitraconazole Cmax ↓ 84%, AUC ↓ 95%	Not recommended
Antineoplastics Agents		
Idelalisib	Although not studied directly, idelalisib is likely to increase the concentrations of itraconazole.	Use with caution
Antivirals for Systemic Use		
Ombitasvir/Paritaprevir/Ritonavir(with or without Dasabuvir)	Although not studied directly, these drugs are expected to increase the concentrations of itraconazole.	Contraindicated
Efavirenz 600 mg	Itraconazole Cmax ↓ 37%, AUC ↓ 39%;Hydroxyitraconazole Cmax ↓ 35%, AUC ↓ 37%	Not recommended
Nevirapine PO 200 mg OD	Itraconazole Cmax ↓ 38%, AUC ↓ 62%	Not recommended

Cobicistat, Darunavir (boosted),Elvitegravir (ritonavir-boosted),Fosamprenavir (ritonavir-boosted), Ritonavir, Saquinavir(ritonavir-boosted)	Although not studied directly, these drugs are expected to increase the concentrations of itraconazole.	Use with caution
Indinavir PO 800 mg TID	Itraconazole concentration ↑	Use with caution
Calcium Channel Blockers		
Diltiazem	Although not studied directly, diltiazem is likely to increase the concentration of itraconazole.	Use with caution
Drugs for Acid Related Disorders		
Antacids (aluminium, calcium,magnesium, or sodiumbicarbonate), H2-receptorantagonists (eg, cimetidine,ranitidine), Proton pumpinhibitors (eg, lansoprazole,omeprazole, rabeprazole)	Itraconazole Cmax ↓, AUC ↓	Use with caution
Respiratory System: Other Respiratory System Products		
Lumacaftor/Ivacaftor PO200/250 mg BID	Itraconazole concentration ↓	Not recommended
Miscellaneous		
St. John's Wort (*Hypericum perforatum*)	Although not studied directly, St. John's Wort is likely to decrease the concentration of itraconazole.	Not recommended

Table 2 Examples of drugs that may have their plasma concentrations impacted by itraconazole, presented by drug class

Medicinal products (PO Single Dose unless otherwise stated) within class	**Expected/Potential effect on drug levels** (↑ = increase; ↔ = no change; ↓ =decrease)	**Clinical comment (see above for additional info and also sections 4.3 and 4.4)**
Analgesics; Anaesthetics		
Ergot alkaloids (eg,dihydroergotamine,ergometrine, ergotamine,methylergometrine)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated

Eletriptan, Fentanyl	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Alfentanil, Buprenorphine (IVand sublingual), Cannabinoids,Methadone, Sufentanil	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Oxycodone PO 10 mg,	Oxycodone PO: Cmax ↑ 45%, AUC ↑ 2.4-fold	Use with caution
Oxycodone IV 0.1 mg/kg	Oxycodone IV: AUC ↑ 51%	Use with caution
Anti-bacterials for Systemic Use; Anti-mycobacterials; Antimycotics for Systemic Use		
Isavuconazole	Although not studied directly, itraconazole is likely to increase the concentrations of isavuconazole.	Contraindicated
Bedaquiline	Although not studied directly, itraconazole is likely to increase the concentrations of bedaquiline.	Not recommended
Rifabutin PO 300 mg OD	Rifabutin concentration ↑ (extent unknown)	Not recommended
Clarithromycin PO 500 mg BID	Clarithromycin concentration ↑	Use with caution
Delamanid	Although not studied directly, itraconazole is likely to increase the concentrations of delamanid.	Use with caution
Antiepileptics		
Carbamazepine	Although not studied directly, itraconazole is likely to increase the concentrations of carbamazepine.	Not recommended
Anti-inflammatory and Antirheumatic Products		
Meloxicam 15 mg	Meloxicam Cmax ↓ 64%, AUC ↓ 37%	Use with caution
Anthelmintics; Antiprotozoals		
Halofantrine	Although not studied directly, itraconazole is	Contraindicated

	likely to increase the concentrations of these drugs.	
Artemether-lumefantrine,Praziquantel	Although not studied directly, itraconazoleis likely to increase the concentrations of these drugs.	Use with caution
Quinine 300 mg	Quinine Cmax ↔, AUC ↑ 96%	Use with caution
Antihistamines for Systemic Use		
Astemizole, Mizolastine,Terfenadine	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Ebastine 20 mg	Ebastine Cmax ↑ 2.5-fold, AUC ↑ 6.2-fold Carebastine Cmax ↔, AUC ↑ 3.1-fold	Not recommended
Bilastine, Rupatadine	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Antineoplastic Agents		
Irinotecan	Although not studied directly, itraconazole is likely to increase the concentrations of irinotecan and its active metabolite.	Contraindicated
Axitinib, Bosutinib, Cabazitaxel,Cabozantinib, Ceritinib,Crizotinib, Dabrafenib,Dasatinib, Docetaxel,Everolimus, Ibrutinib, Lapatinib,Nilotinib, Pazopanib,Regorafenib, Sunitinib,Temsirolimus, Trabectedin,Trastuzumab emtansine, Vincaalkaloids (eg, vinflunine,vinorelbine)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs except for cabazitaxel and regorafenib. No statistically significant change in cabazitaxel exposure, but a high variability in the results was observed. Regorafenib AUC is expected to decrease (by estimation of active moiety)	Not recommended
Cobimetinib 10 mg	Cobimetinib Cmax ↑ 3.2-fold, AUC ↑ 6.7-fold	Not recommended
Olaparib 100 mg	Olaparib Cmax ↑ 40%, AUC ↑ 2.7-fold	Not recommended
Alitretinoin (oral), Bortezomib,Brentuximab vedotin, Erlotinib,Idelalisib, Imatinib,	Although not studied directly, itraconazole is	Use with caution

Nintedanib,Panobinostat, Ponatinib,Ruxolitinib, Sonidegib,	likely to increase the concentrations of these drugs	
Busulfan 1 mg/kg Q6h	Busulfan Cmax ↑, AUC ↑	Use with caution
Gefitinib 250 mg	Gefitinib 250 mg Cmax ↑, AUC ↑ 78%	Use with caution
Antithrombotic Agents		
Dabigatran, Ticagrelor	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Apixaban, Rivaroxaban,Vorapaxar	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Cilostazol, Coumarins (eg,warfarin)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs	Use with caution
Antivirals for Systemic Use		
Ombitasvir/Paritaprevir/Ritonavir(with or without Dasabuvir)	Itraconazole may increase paritaprevir concentration.	Contraindicated
Elbasvir/Grazoprevir,Simeprevir, Tenofoviralafenamide fumarate (TAF),Tenofovir disoproxil fumarate(TDF)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Cobicistat, Elvitegravir (ritonavir-boosted),Glecaprevir/Pibrentasvir,Maraviroc, Ritonavir, Saquinavir	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Indinavir PO 800 mg TID	Indinavir Cmax ↔, AUC ↑	Use with caution
Cardiovascular System (Agents Acting on the Renin-Angiotensin System; Antihypertensives; Beta BlockingAgents; Calcium Channel Blockers; Cardiac Therapy; Diuretics)		
Bepridil, Disopyramide,Dofetilide, Dronedarone,Eplerenone, Ivabradine,Lercanidipine, Nisoldipine,Ranolazine, Sildenafil(pulmonary hypertension)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Aliskiren 150 mg	Aliskiren Cmax ↑ 5.8-fold, AUC ↑ 6.5-fold	Contraindicated
Quinidine 100 mg	Quinidine Cmax ↑ 59%,	Contraindicated

	AUC ↑ 2.4-fold	
Felodipine 5 mg	Felodipine Cmax ↑ 7.8-fold, AUC ↑ 6.3-fold	Not recommended
Riociguat, Tadalafil (pulmonaryhypertension)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Bosentan, Diltiazem,Guanfacine, OtherDihydropyridines (eg,amlodipine, isradipine,nifedipine, nimodipine),Verapamil	Although not studied directly, itraconazole is likely to increase the concentrations of bosentan.	Use with caution
Digoxin 0.5 mg	Digoxin Cmax ↑ 34%, AUC ↑ 68%	Use with caution
Nadolol 30 mg	Nadolol Cmax ↑ 4.7-fold, AUC ↑ 2.2-fold	Use with caution
Corticosteroids for Systemic Use; Drugs for Obstructive Airway Diseases		
Ciclesonide, Salmeterol	Although not studied directly, itraconazole is likely to increase the concentrations of salmeterol and the active metabolite of ciclesonide.	Not recommended
Budesonide INH 1 mg SD	Budesonide INH Cmax ↑ 65%, AUC ↑ 4.2-fold; Budesonide (other formulations)concentration ↑	Use with caution
Dexamethasone IV 5 mg Dexamethasone PO 4.5 mg	Dexamethasone IV: Cmax ↔, AUC ↑ 3.3-fold Dexamethasone PO: Cmax ↑ 69%, AUC ↑3.7-fold	Use with caution
Fluticasone INH 1 mg BID	Fluticasone INH concentration ↑	Use with caution
Methylprednisolone 16 mg	Methylprednisolone PO Cmax ↑ 92%, AUC↑ 3.9-fold Methylprednisolone IV AUC ↑ 2.6-fold	Use with caution
Fluticasone nasal	Although not studied directly, itraconazole is likely to increase the concentrations of nasally-administered fluticasone.	Use with caution
Drugs Used in Diabetes		
Repaglinide 0.25 mg	Repaglinide Cmax ↑ 47%, AUC ↑ 41%	Use with caution
Saxagliptin	Although not studied	Use with caution

	directly, itraconazole is likely to increase the concentrations of saxagliptin.	
Gastrointestinal Drugs, including Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents;Antiemetics and Antinauseants; Drugs for Constipation; Drugs for Functional Gastrointestinal Disorders		
Cisapride, Naloxegol	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Domperidone 20 mg	Domperidone Cmax ↑ 2.7-fold, AUC ↑ 3.2-fold	Contraindicated
Aprepitant, Loperamide,Netupitant	Although not studied directly, itraconazole is likely to increase the concentrations of aprepitant.	Use with caution
Immunosuppressants		
Sirolimus (rapamycin)	Although not studied directly, itraconazole is likely to increase the concentrations of sirolimus.	Not recommended
Cyclosporine, Tacrolimus	Although not studied directly, itraconazole is likely to increase the concentrations of cyclosporine.	Use with caution
Tacrolimus IV 0.03 mg/kg OD	Tacrolimus IV concentration ↑	Use with caution
Lipid Modifying Agents		
Lomitapide	Although not studied directly, itraconazole is likely to increase the concentrations oflomitapide.	Contraindicated
Lovastatin 40 mg,	Lovastatin Cmax ↑ 14.5->20-fold, AUC ↑>14.8 - >20-fold Lovastatin acid Cmax ↑ 11.5-13-fold, AUC ↑15.4-20-fold	Contraindicated
Simvastatin 40 mg	Simvastatin acid Cmax ↑ 17-fold, AUC ↑ 19-fold	Contraindicated

Atorvastatin	Atorvastatin acid: Cmax ↔ to ↑2.5-fold,AUC ↑ 40% to 3-fold	Not recommended
Psychoanaleptics; Psycholeptics (eg, antipsychotics, anxiolytics, and hypnotics)		
Lurasidone, Pimozide,Quetiapine, Sertindole	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Midazolam (oral) 7.5 mg	Midazolam (oral) Cmax ↑ 2.5 to 3.4-fold,AUC ↑ 6.6 to 10.8-fold	Contraindicated
Triazolam 0.25 mg	Triazolam Cmax ↑, AUC ↑	Contraindicated
Alprazolam 0.8 mg	Alprazolam Cmax ↔, AUC ↑ 2.8-fold	Use with caution
Aripiprazole 3 mg	Aripiprazole Cmax ↑ 19%, AUC ↑ 48%	Use with caution
Brotizolam 0.5 mg	Brotizolam Cmax ↔, AUC ↑ 2.6-fold	Use with caution
Buspirone 10 mg	Buspirone Cmax ↑ 13.4-fold, AUC ↑ 19.2-fold	Use with caution
Midazolam (iv) 7.5 mg	Midazolam (iv) 7.5 mg: concentration ↑; Although not studied directly, itraconazole is likely to increase the concentrations of midazolam following oromucosal administration.	Use with caution
Risperidone 2-8 mg/day	Risperidone and active metabolite concentration ↑	Use with caution
Zopiclone 7.5 mg	Zopiclone Cmax ↑ 30%, AUC ↑ 70%	Use with caution
Cariprazine, Galantamine,Haloperidol, Reboxetine,Venlafaxine	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Respiratory System: Other Respiratory System Products		

Lumacaftor/Ivacaftor PO200/250 mg BID	Ivacaftor Cmax ↑ 3.6-fold, AUC ↑ 4.3-fold Lumacaftor Cmax ↔, AUC ↔	Not recommended
Ivacaftor	Although not studied directly, itraconazole is likely to increase the concentrations of ivacaftor.	Use with caution
Sex Hormones and Modulators of the Genital System; Other Gynaecologicals		
Cabergoline, Dienogest,Ulipristal	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Urologicals		
Avanafil, Dapoxetine,Darifenacin	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Contraindicated
Fesoterodine	Although not studied directly, itraconazole is likely to increase the concentrations of the active metabolites, 5-hydroxymethyltolterodine.	Moderate or severe renal or hepatic impairment: Contraindicated Mild renal or hepatic impairment: Concomitant use should be avoided Normal renal or hepatic function: Use with caution with a maximum esoterodine dose of 4 mg.
Solifenacin	Although not studied directly, itraconazole is likely to increase the concentrations of solifenacin.	Severe renal impairment: Contraindicated Moderate or severe hepatic impairment: Contraindicated Use with caution in all other patients with a maximum solifenacin dose of 5 mg.
Vardenafil	Although not studied directly, itraconazole is likely to increase the concentrations of vardenafil.	Contraindicated in patients older than 75years; otherwise not recommended.

Alfuzosin, Silodosin, Tadalafil(erectile dysfunction and benignprostatic hyperplasia),Tamsulosin, Tolterodine	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Not recommended
Dutasteride, Imidafenacin,Sildenafil (erectile dysfunction)	Although not studied directly, itraconazole is likely to increase the concentrations of these drugs.	Use with caution
Oxybutynin 5 mg	Oxybutynin Cmax ↑ 2-fold, AUC ↑ 2-fold N-desethyloxybutynin Cmax ↔, AUC ↔ Following transdermal administration: Although not studied directly, itraconazole is likely to increase the concentrations of oxybutynin following transdermal administration.	Use with caution
Miscellaneous Drugs and Other Substances		
Colchicine	Although not studied directly, itraconazole is likely to increase the concentrations of colchicine	Contraindicated in patients with renal or hepatic impairment. Not recommended in other patients.
Eliglustat	Although not directly studied, itraconazole is expected to increase the concentrations of eliglustat.	Contraindicated in CYP2D6 poor metabolisers (PM). Contraindicated in CYP2D6 intermediate metabolisers (IMs) or extensive metabolisers (EMs) taking a strong or moderate CYP2D6 inhibitor. Use with caution in CYP2D6 IMs and EMs. In CYP2D6 EMs with mild hepatic impairment, an eliglustat dose of 84mg/day should be considered.
Cinacalcet	Although not studied directly, itraconazole is likely to increase the concentrations of cinacalcet.	Use with caution

4.6 Fertility, pregnancy and lactation

Pregnancy

Itraconazole Oral Solution must not be used during pregnancy except for life-threatening cases where the potential benefit to the mother outweighs the potential harm to the foetus (see 4.3).

In animals studies Itraconazole have shown reproductive toxicity (see section 5.3).

Epidemiological data on exposure to itraconazole during the first trimester of pregnancy – mostly in patients receiving short-term treatment for vulvovaginal candidosis – did not show an increased risk for malformations as compared to control subjects not exposed to any known teratogens. Itraconazole has been shown to cross the placenta in a rat model.

Women of child-bearing potential

Women of childbearing potential taking Itraconazole Oral Solution should use effective contraception during treatment. Effective contraception should be continued until the next menstrual period following the end of itraconazole therapy.

Breast-feeding

A very small amount of itraconazole is excreted in human milk. Itraconazole Oral Solution must not be used during lactation.

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed. When driving vehicles and operating machinery the possibility of adverse reactions such as dizziness, visual disturbances and hearing loss (see Section 4.8) which may occur in some instances, must be taken into account.

4.8 Undesirable effects

Summary of the safety profile

The most frequently reported adverse drug reactions (ADRs) with Itraconazole Oral Solution treatment identified from clinical trials and/or from spontaneous reporting were dizziness, headache, dysgeusia, dyspnoea, cough, abdominal pain, diarrhoea, vomiting, nausea, dyspepsia, rash, and pyrexia. The most

serious ADRs were serious allergic reactions, cardiac failure/congestive heart failure/pulmonary oedema, pancreatitis, serious hepatotoxicity (including some cases of fatal acute liver failure), and serious skin reactions. Refer to subsection Tabulated list of adverse reactions for the frequencies and for other observed ADRs. Refer to section 4.4 (Special warnings and precautions for use) for additional information on other serious effects.

Tabulated list of adverse reactions

The ADRs in the table below were derived from double-blind and open-label clinical trials with Itraconazole Oral Solution involving 889 patients for the treatment of oropharyngeal and esophageal candidiasis, and from spontaneous reporting.

The table below presents adverse drug reactions by System Organ Class. Within each System Organ Class, the adverse drug reactions are presented by incidence, using the following convention:

Very common (≥ 1/10); Common (≥ 1/100 to < 1/10); Uncommon (≥ 1/1,000 to < 1/100); Rare (≥1/10,000 to < 1/1,000); Very rare (< 1/10,000), Not known (cannot be estimated from the available data).

Adverse Drug Reactions	
Blood and lymphatic system disorders	
Uncommon	Leukopenia, Thrombocytopenia
Immune system disorders	
Uncommon	Hypersensitivity*
Not Known	Serum Sickness, Angioneurotic Oedema, Anaphylactic Reaction
Metabolism and nutrition disorders	
Uncommon	Hypokalemia
Not Known	Hypertriglyceridemia
Nervous system disorders	
Common	Headache, Dizziness, Dysgeusia
Uncommon	Peripheral Neuropathy*, Paraesthesia, Hypoaesthesia
Eye disorders	
Uncommon	Visual Disturbances (including blurred vision and diplopia)
Ear and labyrinth disorder	

Uncommon	Tinnitus
Not Known	Transient or permanent hearing loss*
Cardiac disorders	
Uncommon	Cardiac failure
Not Known	Congestive Heart Failure*
Respiratory, thoracic and mediastinal disorders	
Common	Dyspnoea, Cough
Gastrointestinal disorders	
Common	Abdominal Pain, Vomiting, Nausea, Diarrhoea, , Dyspepsia
Uncommon	Constipation
Not Known	Pancreatitis
Hepatobiliary disorders	
Uncommon	Hyperbilirubinaemia, Hepatic failure*
Not Known	Serious Hepatotoxicity (including some cases of fatal Acute hepatic failure*)
Skin and subcutaneous tissue disorders	
Common	Rash
Uncommon	Pruritus, Urticaria
Not Known	Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalised exanthematous pustulosis, erythema multiforme, exfoliative dermatitis, leukocytoclastic vasculitis, alopecia, photosensitivity
Musculoskeletal and connective tissue disorders	
Uncommon	Myalgia, arthralgia
Reproductive system and breast disorders	
Uncommon	Menstrual disorders
General disorders and administration site conditions	
Common	Pyrexia
Uncommon	Oedema
Investigations	
Not Known	Blood creatine phosphokinase increased

* see section 4.4.

Description of selected adverse reactions

The following is a list of additional ADRs associated with itraconazole that have been reported in clinical trials of Itraconazole Capsules and Itraconazole IV, excluding the ADR term “Injection site inflammation”, which is specific to the injection route of administration.

Infections and infestations: Sinusitis, Upper respiratory tract infection, Rhinitis
Blood and lymphatic system disorders: Granulocytopenia
Immune system disorders: Anaphylactoid reaction
Metabolism and nutrition disorders: Hyperglycaemia, Hyperkalaemia, Hypomagnesaemia
Psychiatric disorders: Confusional state
Nervous system disorders: Somnolence, Tremor
Cardiac disorders: Left ventricular failure, Tachycardia
Vascular disorders: Hypertension, Hypotension
Respiratory, thoracic and mediastinal disorders: Pulmonary oedema, Dysphonia
Gastrointestinal disorders: Gastrointestinal disorder, Flatulence
Hepatobiliary disorders: Hepatic function abnormal, Hepatitis, Jaundice
Skin and subcutaneous tissue disorders: Rash erythematous, Hyperhidrosis
Renal and urinary disorders: Renal impairment, Pollakiuria, Urinary incontinence
Reproductive system and breast disorders: Erectile dysfunction
General disorders and administration site conditions: Generalised oedema,Face oedema, Chest pain, Pain, Fatigue, Chills
Investigations: Alanine aminotransferase increased, Aspartate aminotransferase increased, Blood alkaline phosphatase increased, Blood lactate dehydrogenase increased, Blood urea increased, Gamma-glutamyl transferase increased, Hepatic enzyme increased, Urine analysis abnormal

Paediatric Population

The safety of Itraconazole Oral Solution was evaluated in 250 paediatric patients aged 6 months to 14 years who participated in five open-label clinical trials. These patients received at least one dose of Itraconazole Oral Solution for prophylaxis of fungal infections or for treatment of oral thrush or systemic fungal infections and
provided safety data.

Based on pooled safety data from these clinical trials, the very common reported ADRs in paediatric patients were Vomiting (36.0%), Pyrexia (30.8%), Diarrhoea (28.4%), Mucosal inflammation (23.2%), Rash (22.8%), Abdominal pain (17.2%), Nausea (15.6%), Hypertension (14.0%), and Cough (11.2%). The nature of ADRs in paediatric patients is similar to that observed in adult subjects, but the incidence is higher in the paediatric patients.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9 Overdose

Symptoms

In general, adverse events reported with overdose have been consistent with adverse drug reactions already listed in this SmPC for itraconazole (see section 4.8).

Management

In the event of an overdose, supportive measures should be employed. Itraconazole cannot be removed by haemodialysis. No specific antidote is available.

5 PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antimycotic for systemic use, triazole derivative.

ATC code: J02A C02

Mechanism of action

Itraconazole inhibits fungal 14α-demethylase, resulting in a depletion of ergosterol and disruption of membrane synthesis by fungi.

PK/PD relationship

The PK/PD relationship for itraconazole, and for triazoles in general, is poorly understood and is complicated by limited understanding of antifungal pharmacokinetics.

Mechanism(s) of resistance

Resistance of fungi to azoles appears to develop slowly and is often the result of several genetic mutations. Mechanisms that have been described are:

• Over-expression of *ERG11*, the gene that encodes 14-alpha-demethylase (the target enzyme)

• Point mutations in *ERG11* that lead to decreased affinity of 14-alpha-demethylase for itraconazole

• Drug-transporter over-expression resulting in increased efflux of itraconazole from fungal cells (i.e., removal of itraconazole from its target)

• Cross-resistance. Cross-resistance amongst members of the azole class of drugs has been observed within *Candida* species though resistance to one member of the class does not necessarily confer resistance to other azoles.

Breakpoints

Breakpoints for itraconazole have not yet been established for fungi using EUCAST methods.

Using CLSI methods, breakpoints for itraconazole have only been established for *Candida* species from superficial mycotic infections. The CLSI breakpoints are: susceptible ≤ 0.125 mg/L and resistant ≥ 1 mg/L.

The prevalence of acquired resistance may vary geographically and with time for selected species, and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.

The *in vitro* susceptibility of fungi to itraconazole depends on the inoculum size, incubation temperature, growth phase of the fungi, and the culture medium used. For these reasons, the minimum inhibitory concentration of itraconazole may vary widely. Susceptibility in the table below is based on MIC_{90} < 1 mg itraconazole/L. There is no correlation between *in vitro* susceptibility and clinical efficacy.

Commonly susceptible species
Aspergillus spp.[2]
Blastomyces dermatitidis[1]
Candida albicans
Candida parapsilosis
Cladosporium spp.
Coccidioides immitis[1]
Cryptococcus neoformans
Epidermophyton floccosum
Fonsecaea spp. [1]
Geotrichum spp.
Histoplasma spp.
Malassezia (formerly Pityrosporum) spp.
Microsporum spp.
Paracoccidioides brasiliensis[1]
Penicillium marneffei[1]
Pseudallescheria boydii

Sporothrix schenckii
Trichophyton spp.
Trichosporon spp.
Species for which acquired resistance may be a problem
Candida glabrata[3]
Candida krusei
Candida tropicalis[3]
Inherently resistant organisms
Absidia spp.
Fusarium spp.
Mucor spp.
Rhizomucor spp.
Rhizopus spp.
Scedosporium proliferans
Scopulariopsis spp.

[1] These organisms may be encountered in patients who have returned from travel outside Europe.

[2] Itraconazole-resistant strains of *Aspergillus fumigatus* have been reported.

[3] Natural intermediate susceptibility.

Paediatric Population

The tolerability and safety of itraconazole oral solution was studied in the prophylaxis of fungal infections in 103 neutropenic paediatric patients aged 0 to14 years (median 5 years) in an open-label uncontrolled phase III clinical study. Most patients (78%) were undergoing allogenic bone marrow transplantation for haematological malignancies. All patients received 5 mg/kg/day of itraconazole oral solution as a single or divided dose. Due to the design of the study, no formal conclusion with regard to efficacy could be derived. The most common adverse events considered definitely or possibly related to itraconazole were vomiting, abnormal liver function, and abdominal pain.

5.2 Pharmacokinetic properties

5.2 Pharmacokinetic properties

Itraconazole

General pharmacokinetic characteristics
Peak plasma concentrations are reached within 2.5 hours following administration of the oral solution. As a consequence of non-linear

pharmacokinetics, itraconazole accumulates in plasma during multiple dosing. Steady-state concentrations are generally reached within about 15 days, with Cmax and AUC values 4 to 7-fold higher than those seen after a single dose. Steady-state Cmax values of about 2µg/ml are reached after oral administration of 200mg once daily. The terminal half life of itraconazole generally ranges from 16 to 28 hours after single dose and increases to 34 to 42 hours with repeated dosing. Once treatment is stopped, itraconazole plasma concentrations decrease to an almost undetectable concentration within 7 to 14 days, depending on the dose and duration of treatment. Itraconazole mean total plasma clearance following intravenous administration is 278ml/min. Itraconazole clearance decreases at higher doses due to saturable hepatic metabolism.

Absorption

Itraconazole is rapidly absorbed after administration of the oral solution. Peak plasma concentrations of itraconazole are reached within 2.5 hours following administration of the oral solution under fasting conditions. The observed absolute bioavailability of itraconazole under fed conditions is about 55% and increases by 30 % when the oral solution is taken in fasting conditions. Itraconazole exposure is greater with the oral solution than with the capsule formulation when the same dose of drug is given (see section 4.4).

Distribution

Most of the itraconazole in plasma is bound to protein (99.8%) with albumin being the main binding component (99.6% for the hydroxy- metabolite). It has also a marked affinity for lipids. Only 0.2% of the itraconazole in plasma is present as free drug. Itraconazole is distributed in a large apparent volume in the body (> 700 L), suggesting its extensive distribution into tissues: Concentrations in lung, kidney, liver, bone, stomach, spleen and muscle were found to be two to three times higher than corresponding concentrations in plasma and the uptake into keratinous tissues, skin in particular, up to four times higher. Concentrations in the cerebrospinal fluid are much lower than in plasma, but efficacy has been demonstrated against infections present in the cerebrospinal fluid.

Metabolism

Itraconazole is extensively metabolised by the liver into a large number of metabolites. *In* vitro studies have shown that CYP3A4 is the major enzyme involved in the metabolism of itraconazole. The main metabolite is hydroxy-itraconazole, which has *in vitro* antifungal activity comparable to itraconazole; trough plasma concentrations of this metabolite are about twice those of itraconazole.

Elimination

Itraconazole is excreted mainly as inactive metabolites in urine (35%) and in faeces (54%) within one week of an oral solution dose. Renal excretion of itraconazole and the active metabolite hydroxyl-itraconazole account for less than 1% of an intravenous dose. Based on an oral radiolabelled dose, faecal excretion of unchanged drug ranges from 3% to 18% of the dose.

As re-distribution of itraconazole from keratinous tissues appears to be negligible, elimination of itraconazole from these tissues is related to epidermal regeneration. Contrary to plasma, the concentration in skin persists for 2 to 4 weeks after discontinuation of a 4-week treatment and in nail keratin – where itraconazole can be detected as early as 1 week after start of treatment – for at least six months after the end of a 3-month treatment period.

Special Populations

Hepatic Impairment

Itraconazole is predominantly metabolised in the liver. A pharmacokinetic study was conducted in six healthy and 12 cirrhotic subjects who were administered a single 100mg dose of itraconazole as a capsule. A statistically significant reduction in average C_{max} (47%) and a twofold increase in the elimination half-life (37 ± 17 versus 16 ±5 hours) of itraconazole were noted in cirrhotic subjects compared with healthy subjects. However, overall exposure to itraconazole, based on AUC, was similar in cirrhotic patients and in healthy subjects.

Data are not available in cirrhotic patients during long-term use of itraconazole (see sections 4.2 and 4.4).

Renal Impairment

Limited data are available on the use of oral itraconazole in patients with renal impairment. A pharmacokinetic study using a single 200mg dose of itraconazole (four 50mg capsules) was conducted in three groups of patients with renal impairment (uremia: n=7; haemodialysis: n=7; and continuous ambulatory peritoneal dialysis: n=5). In uremic subjects with a mean creatinine clearance of 13ml/min x $1.73m^2$, the exposure, based on AUC, was slightly reduced compared with normal population parameters. This study did not demonstrate any significant effect of haemodialysis or continuous ambulatory peritoneal dialysis on the pharmacokinetics of itraconazole (T_{max}, C_{max} and AUC_{0-8h}). Plasma concentration-versus-time profiles showed wide intersubject variation in all three groups.

After a single intravenous dose, the mean terminal half lives of itraconazole in patients with mild (defined in this study as CrCl 50-79 ml/min), moderate (defined in this study as CrCl 20-49 ml/min), and severe renal impairment (defined in this study as CrCl<20 ml/min) were similar to that in healthy subjects (range of means 42-49 hours vs 48 hours in renally impaired patients and healthy subjects, respectively). Overall exposure to itraconazole, based on AUC, was decreased in patients with moderate and severe renal impairment by approximately 30% and 40%, respectively, as compared with subjects with normal renal function.

Data are not available in renally impaired patients during long-term use of itraconazole. Dialysis has no effect on the half-life or clearance of itraconazole or hydroxyl-itraconazole (see sections 4.2 and 4.4).

Paediatric Population

Two pharmacokinetic studies have been conducted in neutropenic children aged 6 months to 14 years in which itraconazole oral solution was administered 5 mg/kg once or twice daily. The exposure to itraconazole was somewhat higher in older children (6 to 14 years) compared to younger children. In all children, effective
plasma concentrations of itraconazole were reached within 3 to 5 days after initiation of treatment and maintained throughout treatment.

Hydroxypropyl-β-Cyclodextrin

The oral bioavailability of hydroxypropyl-β-cyclodextrin given as a solubiliser of itraconazole in oral solution is on average lower than 0.5% and is similar to that of hydroxypropyl-β-cyclodextrin alone. This low bioavailability of hydroxypropyl-β-cyclodextrin is not modified by the presence of food and is similar after single and repeated administrations.

5.3 Preclinical safety data

Itraconazole
Acute oral toxicity studies with itraconazole in mice, rats, guinea-pigs and dogs indicate a wide safety margin (3- to 16-fold of Maximum Recommended Human Dose [MRHD] based on mg/m^2). Itraconazole is not a primary carcinogen in rats or mice up to 20 and 80 mg/kg, respectively.
Nonclinical data on itraconazole revealed no indications for genotoxicity, primary carcinogenicity or impairment of fertility. At high doses, of 40 and 80 mg/kg/day in rats (1- and 2-fold of MRHD based on mg/m^2), effects were observed in the adrenal cortex, liver and the mononuclear phagocyte system but appear to have a low relevance for the proposed clinical use. Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity and teratogenicity in rats and mice at high doses. A global lower bone mineral density was observed in juvenile dogs after chronic itraconazole administration, and in rats, a decreased bone plate activity, thinning of the zona compacta of the large bones, and an increased bone fragility was observed.

Hydroxypropyl-β-cyclodextrin

Non-clinical data reveal no special hazard for humans based on conventional studies of repeated dose toxicity, genotoxicity, and toxicity to reproduction and development. In a rat carcinogenicity study (at 80 mg/kg dose (2-fold of MRHD based on mg/m^2)), hydroxypropyl-β-cyclodextrin
produced adenocarcinomas in the large intestine and exocrine pancreatic adenocarcinomas. These findings were not observed in a similar mouse

carcinogenicity study. The clinical relevance of the large intestine adenocarcinomas is low and the mechanism of exocrine pancreatic adenocarcinomas induction not considered relevant to humans.

Reproductive toxicology
Itraconazole was found to cause a dose-related increase in maternal toxicity, embryotoxicity, and teratogenicity in rats and mice at 40, 80 and 160 mg/kg (0.5-, 1- and 4-fold of MRHD based on mg/m^2). In rats, the teratogenicity consisted of major skeletal defects; in mice, it consisted of encephaloceles and macroglossia. No teratogenic effects were found in rabbits up to 80 mg/kg dose (4-fold of MRHD based on mg/m^2).

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

Hydroxypropylbetadex
Sorbitol E420
Propylene glycol
Cherry flavour (contains propylene glycol (E1520))
Caramel flavour (contains propylene glycol (E1520) and ethanol)
Sodium saccharin
Hydrochloric acid, concentrated (for pH adjustment)
Sodium hydroxide (for pH adjustment)
Purified water.

6.2 Incompatibilities

In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.

6.3 Shelf life

Six months.
Once the bottle is open, use within 1 month.

6.4 Special precautions for storage

Do not store above 25°C.

Store in the original package.

6.5 Nature and contents of container

Amber Type III glass bottle, sealed with a child resistant, tamper evident, polypropylene screw cap, containing 150ml of solution.

A 30ml graduated measuring cup is provided.

6.6 Special precautions for disposal

No special requirements for disposal.

7 MARKETING AUTHORISATION HOLDER

Focus Pharmaceuticals Ltd
Dashwood House,
69 Old Broad Street,
London, EC2M 1QS, United Kingdom

8 MARKETING AUTHORISATION NUMBER(S)

PL 20046/0088

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

02/10/2013

10 DATE OF REVISION OF THE TEXT

14/09/2023